Salix Pharmaceuticals Ltd (SLXP)

172.81
0.16 0.09
NASDAQ : Health Care
Prev Close 172.65
Open 172.72
Day Low/High 172.71 / 172.96
52 Wk Low/High 86.00 / 172.98
Volume 4.30M
Avg Volume 3.38M
Exchange NASDAQ
Shares Outstanding 64.25M
Market Cap 11.10B
EPS -6.53
P/E Ratio N/A
Div & Yield N.A. (N.A)
Salix Pharmaceuticals Reports 2Q2014 Results

Salix Pharmaceuticals Reports 2Q2014 Results

Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) today announced financial and operating results for the second quarter ended June 30, 2014, and provided other business updates.

Fitz Bits: Buying Opportunity This Week

After moves like last week, buyers tend to nibble.

INVESTOR ALERT – Salix Pharmaceuticals, Ltd.: The Law Offices Of Vincent Wong Investigates The Sale Of Salix Pharmaceuticals, Ltd. To Cosmo Pharmaceuticals S.p.A

INVESTOR ALERT – Salix Pharmaceuticals, Ltd.: The Law Offices Of Vincent Wong Investigates The Sale Of Salix Pharmaceuticals, Ltd. To Cosmo Pharmaceuticals S.p.A

The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Salix Pharmaceuticals, Ltd.

Salix Pharmaceuticals Announces 2Q2014 Financial Results Conference Call And Webcast

Salix Pharmaceuticals Announces 2Q2014 Financial Results Conference Call And Webcast

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will report second quarter 2014 financial results following the close of the U.

INVESTOR ALERT – Salix Pharmaceuticals, Ltd.: The Law Offices Of Vincent Wong Investigates The Sale Of Salix Pharmaceuticals, Ltd.

INVESTOR ALERT – Salix Pharmaceuticals, Ltd.: The Law Offices Of Vincent Wong Investigates The Sale Of Salix Pharmaceuticals, Ltd.

The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Salix Pharmaceuticals, Ltd.

Salix And Pharming Announce FDA Approval Of RUCONEST® For The Treatment Of Acute Angioedema Attacks In Patients With Hereditary Angioedema (HAE)

Salix And Pharming Announce FDA Approval Of RUCONEST® For The Treatment Of Acute Angioedema Attacks In Patients With Hereditary Angioedema (HAE)

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) and Pharming Group NV ( EURONEXT: PHARM) today announced that the Food and Drug Administration has approved RUCONEST ® (C1 Esterase Inhibitor [Recombinant]) 50 IU/kg for...

FDA Office Of Drug Evaluation III Approves Salix’s Request That The FDA Approve The RELISTOR® Subcutaneous Injection SNDA For The Treatment Of Opioid-induced Constipation In Patients With Chronic Non-cancer Pain

FDA Office Of Drug Evaluation III Approves Salix’s Request That The FDA Approve The RELISTOR® Subcutaneous Injection SNDA For The Treatment Of Opioid-induced Constipation In Patients With Chronic Non-cancer Pain

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) and Progenics Pharmaceuticals (NASDAQ:PGNX) today announced that the Food and Drug Administration (FDA or Agency) has informed Salix that RELISTOR ® (methylnaltrexone...

SALIX SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Believe The Merger Between Salix And Cosmo Pharmaceuticals May Be Unfair To Shareholders

SALIX SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Believe The Merger Between Salix And Cosmo Pharmaceuticals May Be Unfair To Shareholders

Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Salix...

Will This Price Target Increase Help Salix Pharmaceuticals (SLXP) Stock Today?

Will This Price Target Increase Help Salix Pharmaceuticals (SLXP) Stock Today?

UBS raises its price target for Salix Pharmaceuticals (SLXP) to $137 from $123 with a 'neutral' rating.

SHAREHOLDER ALERT: Brower Piven Announces The Investigation Of Salix Pharmaceuticals, Ltd. In Connection With The Proposed Sale Of The Company

SHAREHOLDER ALERT: Brower Piven Announces The Investigation Of Salix Pharmaceuticals, Ltd. In Connection With The Proposed Sale Of The Company

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the board of directors of...

3 Big Stocks on Traders' Radars

3 Big Stocks on Traders' Radars

Here's how to trade some of the most active stocks on the market today.

Salix to Invert, Merging With Cosmo Pharma

Salix to Invert, Merging With Cosmo Pharma

Building on the M&A trend for tax inversion deals, Salix Pharmaceuticals and Italy's Cosmo Pharmaceuticals plan to merge.

Salix Prospects as Takeover Target Debated After Inversion Deal

Salix Prospects as Takeover Target Debated After Inversion Deal

Shares of drug maker Salix (SLXP) are falling after the company announced that it had agreed to carry out a merger which is expected to reduce its profits in 2015.

Unusual Social Activity Today Around Salix Pharmaceuticals (SLXP)

Unusual Social Activity Today Around Salix Pharmaceuticals (SLXP)

Trade-Ideas LLC identified Salix Pharmaceuticals (SLXP) as an unusual social activity candidate

Trade-Ideas: Salix Pharmaceuticals (SLXP) Is Today's Post-Market Leader Stock

Trade-Ideas: Salix Pharmaceuticals (SLXP) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified Salix Pharmaceuticals (SLXP) as a post-market leader candidate

Salix Pharmaceuticals To Combine With Cosmo Technologies To Form Salix Pharmaceuticals, Plc

Salix Pharmaceuticals To Combine With Cosmo Technologies To Form Salix Pharmaceuticals, Plc

Salix Pharmaceuticals, Ltd. (“Salix”) (NASDAQ: SLXP) and Cosmo Pharmaceuticals S.

New Lifetime High For Salix Pharmaceuticals (SLXP)

New Lifetime High For Salix Pharmaceuticals (SLXP)

Trade-Ideas LLC identified Salix Pharmaceuticals (SLXP) as a new lifetime high candidate

Will This Price Target Increase Help Salix Pharmaceuticals (SLXP) Stock Today?

Will This Price Target Increase Help Salix Pharmaceuticals (SLXP) Stock Today?

Leerink raised its price target for Salix Pharmaceuticals (SLXP) to $162 from $128, reiterating its 'outperform' rating for the stock.

Salix Pharmaceuticals (SLXP) Strong In Pre-Market Trading

Salix Pharmaceuticals (SLXP) Strong In Pre-Market Trading

Trade-Ideas LLC identified Salix Pharmaceuticals (SLXP) as a pre-market leader candidate

Salix Announces Statistically Significant Primary Endpoint Result For TARGET 3 Evaluating The Efficacy And Safety Of Repeat Treatment With Rifaximin 550mg In Subjects With Irritable Bowel Syndrome With Diarrhea

Salix Announces Statistically Significant Primary Endpoint Result For TARGET 3 Evaluating The Efficacy And Safety Of Repeat Treatment With Rifaximin 550mg In Subjects With Irritable Bowel Syndrome With Diarrhea

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the successful outcome of TARGET 3 – a Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of repeat treatment...

Salix Pharmaceuticals To Host Investor Day On July 9, 2014

Salix Pharmaceuticals To Host Investor Day On July 9, 2014

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) will host an Investor Day on Wednesday, July 9, 2014.

FDA Ad Comm Provides Recommendations Regarding The Potential Cardiovascular Risk Associated With The Class Of Peripherally-active Opioid Receptor Antagonists And The Trials To Support Approval Of Products For OIC

FDA Ad Comm Provides Recommendations Regarding The Potential Cardiovascular Risk Associated With The Class Of Peripherally-active Opioid Receptor Antagonists And The Trials To Support Approval Of Products For OIC

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) and Progenics Pharmaceuticals (NASDAQ:PGNX) today reported that the Anesthetic and Analgesic Drug Products Advisory Committee of the Food and Drug Administration (FDA) has...

5 Health Care Stocks to Trade for Gains in June

5 Health Care Stocks to Trade for Gains in June

Investors in search of healthy gains in 2014 need look no further than health care stocks.

Salix Pharmaceuticals To Present At Three Investment Conferences In June

Salix Pharmaceuticals To Present At Three Investment Conferences In June

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at three investment conferences during June 2014.

First Week Of January 2015 Options Trading For Salix Pharmaceuticals (SLXP)

First Week Of January 2015 Options Trading For Salix Pharmaceuticals (SLXP)

Investors in Salix Pharmaceuticals Ltd saw new options begin trading this week, for the January 2015 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 242 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Salix Pharmaceuticals Larger Than S&P 500 Component DENTSPLY International

Salix Pharmaceuticals Larger Than S&P 500 Component DENTSPLY International

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Salix Pharmaceuticals Ltd was identified as having a larger market cap than the smaller end of the S&P 500, for example DENTSPLY International, Inc. , according to The Online Investor.

Salix Pharmaceuticals Reports 1Q2014 Results

Salix Pharmaceuticals Reports 1Q2014 Results

Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) today announced financial and operating results for the first quarter ended March 31, 2014, and other business updates.

Salix Pharmaceuticals To Present At Two Investment Conferences In May

Salix Pharmaceuticals To Present At Two Investment Conferences In May

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at two investment conferences during May 2014.